Last reviewed · How we verify
Cyclosporine A 0,05% eye drop
Cyclosporine A suppresses T-cell activation and reduces inflammatory cytokine production in the eye, thereby decreasing ocular surface inflammation.
Cyclosporine A suppresses T-cell activation and reduces inflammatory cytokine production in the eye, thereby decreasing ocular surface inflammation. Used for Dry eye disease (keratoconjunctivitis sicca), Ocular surface inflammation.
At a glance
| Generic name | Cyclosporine A 0,05% eye drop |
|---|---|
| Also known as | NOVA22007 |
| Sponsor | Campus Bio-Medico University |
| Drug class | Calcineurin inhibitor |
| Target | Calcineurin (protein phosphatase 2B) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology / Immunology |
| Phase | Phase 3 |
Mechanism of action
Cyclosporine A is a calcineurin inhibitor that blocks T-cell receptor signaling and prevents the transcription of pro-inflammatory cytokines such as IL-2, TNF-α, and IFN-γ. In the eye, this immunosuppressive action reduces the inflammatory cascade responsible for dry eye disease and other ocular surface disorders. The 0.05% ophthalmic formulation delivers the drug topically to maximize local effect while minimizing systemic exposure.
Approved indications
- Dry eye disease (keratoconjunctivitis sicca)
- Ocular surface inflammation
Common side effects
- Ocular irritation / burning sensation
- Conjunctival hyperemia
- Foreign body sensation
- Transient blurred vision
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cyclosporine A 0,05% eye drop CI brief — competitive landscape report
- Cyclosporine A 0,05% eye drop updates RSS · CI watch RSS
- Campus Bio-Medico University portfolio CI